Nature Communications (Aug 2019)
Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML
- Thomas Oellerich,
- Constanze Schneider,
- Dominique Thomas,
- Kirsten M. Knecht,
- Olga Buzovetsky,
- Lars Kaderali,
- Christoph Schliemann,
- Hanibal Bohnenberger,
- Linus Angenendt,
- Wolfgang Hartmann,
- Eva Wardelmann,
- Tamara Rothenburger,
- Sebastian Mohr,
- Sebastian Scheich,
- Federico Comoglio,
- Anne Wilke,
- Philipp Ströbel,
- Hubert Serve,
- Martin Michaelis,
- Nerea Ferreirós,
- Gerd Geisslinger,
- Yong Xiong,
- Oliver T. Keppler,
- Jindrich Cinatl
Affiliations
- Thomas Oellerich
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Constanze Schneider
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Dominique Thomas
- pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University of Frankfurt
- Kirsten M. Knecht
- Department of Molecular Biophysics and Biochemistry, Yale University
- Olga Buzovetsky
- Department of Molecular Biophysics and Biochemistry, Yale University
- Lars Kaderali
- Institute of Bioinformatics, University Medicine Greifswald
- Christoph Schliemann
- Department of Medicine A, University Hospital Münster
- Hanibal Bohnenberger
- Institute of Pathology, University Medical Center
- Linus Angenendt
- Department of Medicine A, University Hospital Münster
- Wolfgang Hartmann
- Gerhard Domagk Institute for Pathology, University Hospital Münster
- Eva Wardelmann
- Gerhard Domagk Institute for Pathology, University Hospital Münster
- Tamara Rothenburger
- Institute of Medical Virology, University of Frankfurt
- Sebastian Mohr
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Sebastian Scheich
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Federico Comoglio
- Department of Haematology, Cambridge Institute of Medical Research, Cambridge University
- Anne Wilke
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Philipp Ströbel
- Institute of Pathology, University Medical Center
- Hubert Serve
- Department of Medicine II, Hematology/Oncology, Goethe University of Frankfurt
- Martin Michaelis
- Industrial Biotechnology Centre and School of Biosciences, University of Kent
- Nerea Ferreirós
- pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University of Frankfurt
- Gerd Geisslinger
- pharmazentrum frankfurt/ZAFES, Institute of Clinical Pharmacology, Goethe University of Frankfurt
- Yong Xiong
- Department of Molecular Biophysics and Biochemistry, Yale University
- Oliver T. Keppler
- Institute of Medical Virology, University of Frankfurt
- Jindrich Cinatl
- Institute of Medical Virology, University of Frankfurt
- DOI
- https://doi.org/10.1038/s41467-019-11413-4
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
In acute myeloid leukemia, hypomethylating agents decitabine and azacytidine are used interchangeably. Here, the authors show that the major metabolite of decitabine, but not azacytidine, is subject to SAMHD1 inactivation, highlighting SAMHD1 as a potential biomarker and therapeutic target
